All stories by Payal Banerjee
SII to raise monthly production to 10 cr doses by Aug, Bharat Biotech promises 7.8 crRediff.com5 days ago
Several states and UTs including Delhi, Maharashtra, Karnataka and Telangana have decided to opt for global tenders for procurement of anti-coronavirus shots with the domestic supply falling short to meet the rising demand.
Covaxin gets nod for phase 2, 3 clinical trials on 2-18 year-oldsRediff.com5 days ago
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
50 lakh Covishield doses meant for export to UK to be used in IndiaRediff.com8 May 2021
50 lakh doses of 'Covishield' vaccine earmarked by the Serum Institute for export to the United Kingdom have now been made available for the inoculation of 18-44 age group in 21 states/UTs in India, amid a surge in COVID-19 cases, official sources said.
Govt asks Serum, Bharat Biotech to lower COVID vaccine costRediff.com26 Apr 2021
The Hyderabad-based Bharat Biotech has fixed the price of its COVID-19 vaccine, Covaxin, at Rs 600 per dose for state governments and at Rs 1,200 per dose for private hospitals. The Pune-based Serum Institute of India, the world's largest vaccine maker in terms of volume, has announced a price of Rs 400 per dose for its COVID-19 vaccine, 'Covishield', for state governments and Rs 600 per dose for private hospitals.
WHO rejects SII's proposal to extend Covishield's shelf lifeRediff.com8 Apr 2021
The move comes even as India's drug regulator has extended Covishield's shelf life from six to nine months from its manufacturing date.
Year after Janata curfew, Covid rears its ugly head againRediff.com22 Mar 2021
Millions of people across the country stayed indoors on March 22, 2020 in an unprecedented and overwhelming response to Prime Minister Narendra Modi's appeal for the nationwide curfew. People used to come out briefly at 5 pm to show their gratitude to healthcare and other essential service providers with sounds of bells, conches and claps.
Need to increase pace of vaccinations: Govt to statesRediff.com21 Feb 2021
While some states are carrying out vaccination twice a week some others are carrying out four or more than four times a week.
Govt places second purchase order for 1 crore doses of CovishieldRediff.com4 Feb 2021
The Centre on Wednesday placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca COVID-19 vaccine 'Covishield', each costing Rs 210, including GST, sources said.
Ahead of Covid vaccine rollout, Centre issues dos and don'tsRediff.com14 Jan 2021
In a letter to all states and Union territories, the ministry highlighted that under the emergency use authorisation, coronavirus vaccination is indicated only for 18 years and above. If required, COVID-19 vaccine and other vaccines should be separated by an interval of at least 14 days.
Govt to buy another 4.5 crore doses of CovishieldRediff.com12 Jan 2021
According to the purchase order placed on Monday, each dose of the vaccine has been priced at Rs 200 and with GST of Rs 10, it would cost Rs 210.
Govt places order for 11 mn doses of Serum vaccine CovishieldRediff.com11 Jan 2021
Dispatch of the vaccine is likely to start by early Tuesday morning, sources said. According to the order placed, each dose of the vaccine has been priced at Rs 200 and with GST of Rs 10, it would cost Rs 210.
Bharat Biotech's Covaxin vaccine cleared by special panelRediff.com2 Jan 2021
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research.
Expert panel recommends granting emergency nod to Oxford vaccineRediff.com2 Jan 2021
As for Bharat Biotech, the Subject Expert Committee (SEC) on COVID-19 of the CDSCO asked the firm to expedite volunteer recruitment for the ongoing clinical trial and said it may conduct interim efficacy analysis for further consideration of restricted emergency use approval for its vaccine Covaxin, they stated.
Oxford vaccine may be first to get nod for emergency use in IndiaRediff.com26 Dec 2020
Once the UK drug regulator gives its approval to the Oxford vaccine, the expert committee on COVID-19 at the Central Drugs Standard Control Organisation (CDSCO) will hold its meeting and thoroughly review the safety and immunogenicity data from the clinical evaluations conducted abroad and in India before granting any emergency authorisation for the vaccine here, official sources said.
Health ministry calls urgent meet to discuss new Covid strain in UKRediff.com20 Dec 2020
A number of European countries have banned flights from the UK as the British government warned that the potent new strain of the virus was "out of control" and imposed a stringent new stay-at-home lockdown from Sunday.
Expert panel seeks more data on SII, Bharat Biotech vaccinesRediff.com10 Dec 2020
An expert committee of the Central Drugs Standard Control Organisation (CDSCO) on Wednesday sought additional safety and efficacy data for COVID-19 vaccine candidates of Serum Institute and Bharat Biotech, after deliberating upon their applications seeking emergency use authorisation for the shots, official sources said.
Bharat Biotech seeks emergency nod for use of CovaxinRediff.com8 Dec 2020
Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Pfizer seeks approval in India for Covid vaccineRediff.com6 Dec 2020
'Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization for its COVID-19 vaccine in India'
Covid vaccination: Govt seeks help of religious leaders to bust mythsRediff.com26 Nov 2020
According to the health ministry, the block task force would be tasked with resolving bottlenecks, thus de-centralising planning and preparedness for vaccine introduction.
1 cr frontline healthcare workers identified to get Covid vaccineRediff.com24 Nov 2020
Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials.